Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Immunic, Inc. (NASDAQ:IMUX) has been given an average rating of “Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and three have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $47.25.

A number of equities analysts have recently commented on IMUX shares. Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wedbush reiterated an “outperform” rating and set a $45.00 price target on shares of Immunic in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th.

Hedge Funds Weigh In On Immunic

Several large investors have recently bought and sold shares of IMUX. Jane Street Group LLC raised its stake in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after buying an additional 219,957 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Immunic during the 3rd quarter worth about $239,000. Two Sigma Investments LP acquired a new position in shares of Immunic during the 3rd quarter worth about $52,000. Finally, Virtu Financial LLC purchased a new position in shares of Immunic in the 3rd quarter valued at about $99,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Immunic stock opened at $11.42 on Monday. The firm has a market capitalization of $155.77 million, a P/E ratio of -2.61 and a beta of 1.41. Immunic has a twelve month low of $5.06 and a twelve month high of $17.43. The stock’s fifty day simple moving average is $14.68 and its 200-day simple moving average is $13.11.

Immunic (NASDAQ:IMUX) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. Sell-side analysts predict that Immunic will post -3.71 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.